[Evidence of iSGLT2 in the treatment of chronic kidney disease]

Abstract

The prevalence and incidence of chronic kidney disease (CKD) is constantly on the rise and it is foreseeable that in the coming decades it will be the main chronic disease in the developed world. CKD is also one of the main causes of cardiovascular morbidity and mortality, with cardiovascular diseases being the main etiology of CKD, so that one and the other feed back into what is known as the cardiorenal axis. Until five years ago, the only pharmacological treatment that had been shown to modify the course of the disease were inhibitors of the renin angiotensin system. However, in recent years, the development of inhibitors of the sodium glucose cotransporter type2 have led to a revolution in cardiovascular and renal protection, both in diabetic and non-diabetic patients, constituting, at present, the cornerstone in the CKD management.

Keywords: Cardiorenal axis; Chronic kidney disease; Eje cardiorrenal; Enfermedad renal crónica; Inhibidores del cotransportador sodio glucosa tipo2; Mortalidad; Mortality; Sodium glucose co-transporter type2 inhibitors.